{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.06","upperLimit":"2.35","value":"0.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"CCND2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.09","upperLimit":"8.09","value":"0.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"SMO"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.10","upperLimit":"13.33","value":"0.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"CCND1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"description":"Whole blood mRNA analyses were performed on 21 mRNA candidates. Only the analytes showing statistically significant change from baseline are reported here.","dispersionType":"Full Range","groups":[{"description":"Participants received oral doses of glasdegib tablets 100 mg QD in 28-day cycles on a continuous basis, starting on Day 1 of Cycle 1. LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28 day cycles.","id":"OG000","title":"Phase 2 Unfit: Glasdegib 100 mg + LDAC"}],"paramType":"MEDIAN","populationDescription":"PD analysis set:all enrolled participants in Phase 2 Unfit who received at least 1 dose of glasdegib, had at least 1 PD parameter with a baseline and an adequate post treatment assessment.","reportingStatus":"POSTED","timeFrame":"Baseline (Cycle 1/Day 1 pre-dose); End of Treatment (maximum of 12 cycles from start of therapy or until disease progression or relapse, participant refusal or unacceptable toxicity occurred, whichever came first, an average of 1 year)","title":"Ratios of mRNA Levels to Baseline at Phase 2 Unfit - End of Treatment","type":"SECONDARY","unitOfMeasure":"ratio"}